AREA 23 | An IPG Health Company
Advertising ServicesNew York, United States1001-5000 Employees
AREA 23 | An IPG Health Company, is a full-service agency focused on pushing creativity and invention in healthcare marketing to new heights. Its “What If” way of working provides a framework for breakthrough ideas that truly drive innovation and keep clients ahead of industry trends. AREA 23 is consistently recognized with the highest industry awards and honors. Med Ad News named AREA 23 “Agency of the Year,” “Most Creative Agency,” and “Most Admired Agency” in 2017—the first time any agency had won the show’s top three awards at once. That is, until AREA 23 did it again in 2018, 2020, and most recently, in 2023. In all, Med Ad News has honored AREA 23 five times as “Agency of the Year,” nine times as “Most Creative Agency,” and eight times as “Most Admired Agency.” In 2019, Clio Health awarded AREA 23 “Agency of the Year” for a third consecutive year, and New York Festivals Global Awards recognized AREA 23 as “Global Agency of the Year.” Cannes Lions, the world’s preeminent annual creative awards festival, awarded AREA 23 the Innovation Grand Prix. At the Medical Marketing & Media (MM+M) Awards, AREA 23 won “Large Agency of the Year” and the Titanium Award for Best in Show. In 2020/2021, Cannes Lions Health honored the agency with its rarely-awarded Pharma Grand Prix, the Radio & Audio Grand Prix, and recognized AREA 23 as “Agency of the Year.” In 2022, AREA 23 won Clio Health "Agency of the Year,” LIA "Health Agency of the Year," "Large Agency of the Year" at the MM+M Awards, “Most Innovative Culture” by Digiday’s WorkLife Awards, and awarded the Grand Prix for Good and "Agency of the Year" at Cannes Lions Health. This is the third time AREA 23 has earned the coveted title within a five-year span, and the first agency to achieve the feat in successive years. AREA 23’s groundbreaking creative is also celebrated in diverse categories, including Brand Experience & Activation, Creative Strategy, Design, Direct, Mobile, and PR.